Mar 07, 2018 7:30am EST ProMIS Neurosciences Announces Gross Proceeds of $1,484,498 Related to the Exercise of Common Stock Warrants
Mar 06, 2018 7:30am EST ProMIS Neurosciences Lead Product Candidate for Alzheimer's Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies
Jan 25, 2018 7:30am EST ProMIS Neurosciences Issues White Paper Entitled: "Not All Amyloid Beta Therapeutics Are Created Equal"
Jan 23, 2018 7:30am EST ProMIS Neurosciences Lead Product Candidate for Alzheimer's Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies
Jan 04, 2018 7:30am EST ProMIS Neurosciences Lead Product Candidate for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies